Identification and characterization of influenza virus entry inhibitors through dual myxovirus high-throughput screening

Journal of Virology

Volumn 90, Issue 16, 2016, Pages 7368-7387

  Weisshaar, Marco ^a   Cox, Robert ^a   Morehouse, Zachary ^a   Kyasa, Shiva Kumar ^b   Yan, Dan ^a   Oberacker, Phil ^a   Mao, Shuli ^b   Golden, Jennifer E ^c   Lowen, Anice C ^d   Natchus, Michael G ^b   Plemper, Richard K ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRP 103594; GRP 115249; GRP 71271 2; GRP 71271 8; INFLUENZA VIRUS HEMAGGLUTININ; UNCLASSIFIED DRUG; VIRUS FUSION INHIBITOR; ANTIVIRUS AGENT; PROTEIN BINDING;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BIOLAYER INTERFEROMETRY; CHEMICAL LIBRARY; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DOSE RESPONSE; DRUG POTENCY; DUAL MYXOVIRUS HIGH THROUGHPUT SCREENING; GENOME; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INFLUENZA A VIRUS; INTERFEROMETRY; MEMBRANE FUSION; MINIGENOME; MOLECULAR DOCKING; MOLECULAR LIBRARY; MUTATION; NONHUMAN; PRIMARY RESISTANCE; PRIORITY JOURNAL; SECONDARY RESISTANCE; SYNTHESIS; VIRUS ENTRY; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; CHEMISTRY; DRUG EFFECTS; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES;

ANTIVIRAL AGENTS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFLUENZA A VIRUS; MUTATION; PROTEIN BINDING; VIRUS INTERNALIZATION;

EID: 84982221275     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00898-16     Document Type: Article

References (67)

1. Fischer WA, II, Gong M, Bhagwanjee S, Sevransky J. 2014. Global burden of influenza as a cause of cardiopulmonary morbidity and mortality. Global Heart 9:325-336. http://dx.doi.org/10.1016/j.gheart.2014.08 .004.
2. Johnson NP, Mueller J. 2002. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 76:105-115. http://dx.doi.org/10.1353/bhm.2002.0022.
3. Salomon R, Webster RG. 2009. The influenza virus enigma. Cell 136: 402-410. http://dx.doi.org/10.1016/j.cell.2009.01.029.
4. Neumann G, Kawaoka Y. 2011. The first influenza pandemic of the new millennium. Influenza Other Respir Viruses 5:157-166. http://dx.doi.org /10.1111/j.1750-2659.2011.00231.x.
5. Reid AH, Taubenberger JK. 1999. The 1918 flu and other influenza pandemics: "over there" and back again. Lab Invest 79:95-101.
6. Thompson WW, Moore MR, Weintraub E, Cheng PY, Jin X, Bridges CB, Bresee JS, Shay DK. 2009. Estimating influenza-associated deaths in the United States. Am J Public Health 99(Suppl 2):S225-S230. http://dx .doi.org/10.2105/AJPH.2008.151944.
7. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12:36-44. http://dx.doi.org/10.1016/S1473-3099(11) 70295-X.
8. Ebell MH, Call M, Shinholser J. 2013. Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials. Fam Pract 30:125-133. http://dx.doi.org/10.1093/fampra/cms059.
9. Le QM, Wertheim HF, Tran ND, van Doorn HR, Nguyen TH, Horby P, Vietnam H1N1 Investigation Team. 2010. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza.NEngl J Med 362:86-87. http://dx.doi.org/10.1056/NEJMc0910732.
10. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Koike K, Mitamura K, Kawaoka Y. 2007. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297:1435-1442.
11. van der Vries E, Stelma FF, Boucher CA. 2010. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 363: 1381-1382. http://dx.doi.org/10.1056/NEJMc1003749.
12. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, Lindstrom S, Shay DK, Marshfield Influenza Study Group. 2009. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 199:159-167. http://dx.doi.org/10.1086/595861.
13. Chamberlain AT, Wells K, Seib K, Kudis A, Hannan C, Orenstein WA, Whitney EA, Hinman AR, Buehler JW, Omer SB, Berkelman RL. 2012. Lessons learned from the 2007 to 2009 Haemophilus influenzae type B vaccine shortage: implications for future vaccine shortages and public health preparedness. J Public Health Manag Pract 18:E9-E16. http://dx .doi.org/10.1097/PHH.0b013e31821dce27.
14. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. 2013. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100:446-454. http://dx.doi.org/10.1016/j.antiviral.2013.09.015.
15. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW, Colman PM, Varghese JN, Ryan DM, Woods JM, Bethell RC, Hotham VJ, Cameron JM, Pennet CR. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-423. http://dx.doi.org /10.1038/363418a0.
16. Kim CU, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai CY, Laver WG, Stevens RC. 1997. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent antiinfluenza activity. J Am Chem Soc 119:681-690. http://dx.doi.org/10 .1021/ja963036t.
17. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. 1985. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4:3021-3024.
18. Hayden FG, Hay AJ. 1992. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 176:119-130.
19. Wang J, Wu Y, Ma C, Fiorin G, Wang J, Pinto LH, Lamb RA, Klein ML, Degrado WF. 2013. Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. Proc Natl Acad Sci U S A 110:1315-1320. http://dx.doi.org/10.1073/pnas.1216526110.
20. Carr J, Ives J, Kelly L, Lambkin R, Oxford J, Mendel D, Tai L, Roberts N. 2002. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res 54:79-88. http://dx.doi.org/10.1016/S0166-3542(01)00215-7.
21. Herlocher ML, Carr J, Ives J, Elias S, Truscon R, Roberts N, Monto AS. 2002. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res 54:99-111. http://dx.doi .org/10.1016/S0166-3542(01)00214-5.
22. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108. http://dx.doi .org/10.1038/4371108a.
23. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765. http://dx.doi.org/10.1016/S0140-6736(04)16934-1.
24. Lowen AC, Palese P. 2007. Influenza virus transmission: basic science and implications for the use of antiviral drugs during a pandemic. Infect Disord Drug Targets 7:318 -328. http://dx.doi.org/10.2174 /187152607783018736.
25. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295:891-894. http://dx.doi .org/10.1001/jama.295.8.joc60020.
26. Swinney DC. 2013. The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines. J Biomol Screen 18: 1186-1192. http://dx.doi.org/10.1177/1087057113501199.
27. Swinney DC. 2013. Phenotypic vs. target-based drug discovery for firstin-class medicines. Clin Pharmacol Ther 93:299-301. http://dx.doi.org /10.1038/clpt.2012.236.
28. Karlas A, Machuy N, Shin Y, Pleissner KP, Artarini A, Heuer D, Becker D, Khalil H, Ogilvie LA, Hess S, Maurer AP, Muller E, Wolff T, Rudel T, Meyer TF. 2010. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 463:818-822. http: //dx.doi.org/10.1038/nature08760.
29. Beyleveld G, White KM, Ayllon J, Shaw ML. 2013. New-generation screening assays for the detection of anti-influenza compounds targeting viral and host functions. Antiviral Res 100:120-132. http://dx.doi.org/10 .1016/j.antiviral.2013.07.018.
30. Lutz A, Dyall J, Olivo PD, Pekosz A. 2005. Virus-inducible reporter genes as a tool for detecting and quantifying influenza A virus replication. J Virol Methods 126:13-20. http://dx.doi.org/10.1016/j.jviromet.2005.01 .016.
31. Yan D, Krumm SA, Sun A, Steinhauer DA, Luo M, Moore ML, Plemper RK. 2013. Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response. J Virol 87:11076-11087. http://dx.doi.org/10 .1128/JVI.01425-13.
32. Konig R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Ortigoza MB, Liang Y, Gao Q, Andrews SE, Bandyopadhyay S, De Jesus P, Tu BP, Pache L, Shih C, Orth A, Bonamy G, Miraglia L, Ideker T, Garcia-Sastre A, Young JA, Palese P, Shaw ML, Chanda SK. 2010. Human host factors required for influenza virus replication. Nature 463:813-817. http://dx.doi.org /10.1038/nature08699.
33. Heaton NS, Leyva-Grado VH, Tan GS, Eggink D, Hai R, Palese P. 2013. In vivo bioluminescent imaging of influenza A virus infection and characterization of novel cross-protective monoclonal antibodies. J Virol 87: 8272-8281. http://dx.doi.org/10.1128/JVI.00969-13.
34. Manicassamy B, Manicassamy S, Belicha-Villanueva A, Pisanelli G, Pulendran B, Garcia-Sastre A. 2010. Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci U S A 107:11531-11536. http://dx.doi.org/10.1073/pnas .0914994107.
35. Yan D, Weisshaar M, Lamb K, Chung HK, Lin MZ, Plemper RK. 2015. Replication-competent influenza virus and respiratory syncytial virus luciferase reporter strains engineered for co-infections identify antiviral compounds in combination screens. Biochemistry 54:5589-5604. http: //dx.doi.org/10.1021/acs.biochem.5b00623.
36. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 97:6108-6113. http://dx.doi.org/10 .1073/pnas.100133697.
37. Jacob RT, Larsen MJ, Larsen SD, Kirchhoff PD, Sherman DH, Neubig RR. 2012. MScreen: an integrated compound management and highthroughput screening data storage and analysis system. J Biomol Screen 17:1080-1087. http://dx.doi.org/10.1177/1087057112450186.
38. Hotard AL, Shaikh FY, Lee S, Yan D, Teng MN, Plemper RK, Crowe JE, Jr, Moore ML. 2012. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 434:129-136. http://dx.doi.org/10.1016/j.virol.2012.09.022.
39. Dahlin JL, Baell J, Walters MA. 18 September 2015. Assay interference by chemical reactivity. In Sittampalam GS, Coussens NP, Nelson H, Arkin M, Auld D, Austin C, Bejcek B, Glicksman M, Inglese J, Iversen PW, Li Z, McGee J, McManus O, Minor L, Napper A, Peltier JM, Riss T, Trask OJ, Jr, Weidner J (ed), Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MD. http://www.ncbi.nlm.nih.gov/books/NBK326709/.
40. Brideau C, Gunter B, Pikounis B, Liaw A. 2003. Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen 8:634-647. http://dx.doi.org/10.1177/1087057103258285.
41. Gamblin SJ, Skehel JJ. 2010. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 285:28403-28409. http://dx.doi .org/10.1074/jbc.R110.129809.
42. Sun A, Ndungu JM, Krumm SA, Yoon JJ, Thepchatri P, Natchus M, Plemper RK, Snyder JP. 2011. Host-directed inhibitors of myxoviruses: synthesis and in vitro biochemical evaluation. ACS Med Chem Lett 2:798-803. http://dx.doi.org/10.1021/ml200125r.
43. Krumm SA, Ndungu JM, Yoon JJ, Dochow M, Sun A, Natchus M, Snyder JP, Plemper RK. 2011. Potent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerases. PLoS One 6:e20069. http://dx.doi.org/10.1371/journal.pone.0020069.
44. Beckett D, Kovaleva E, Schatz PJ. 1999. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci 8:921-929.
45. White KM, De Jesus P, Chen Z, Abreu P, Jr, Barile E, Mak PA, Anderson P, Nguyen QT, Inoue A, Stertz S, Koenig R, Pellecchia M, Palese P, Kuhen K, Garcia-Sastre A, Chanda SK, Shaw ML. 2015. A potent anti-influenza compound blocks fusion through stabilization of the prefusion conformation of the hemagglutinin protein. ACS Infect Dis 1:98-109. http://dx.doi.org/10.1021/id500022h.
46. Lai KK, Cheung NN, Yang F, Dai J, Liu L, Chen Z, Sze KH, Chen H, Yuen KY, Kao RY. 2015. Identification of novel fusion inhibitors of influenza A virus by chemical genetics. J Virol 90:2690-2701. http://dx .doi.org/10.1128/JVI.02326-15.
47. Basu A, Antanasijevic A, Wang M, Li B, Mills DM, Ames JA, Nash PJ, Williams JD, Peet NP, Moir DT, Prichard MN, Keith KA, Barnard DL, Caffrey M, Rong L, Bowlin TL. 2014. New small molecule entry inhibitors targeting hemagglutinin-mediated influenza A virus fusion. J Virol 88:1447-1460. http://dx.doi.org/10.1128/JVI.01225-13.
48. Foulkes-Murzycki JE, Rosi C, Kurt Yilmaz N, Shafer RW, Schiffer CA. 2013. Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease. ACS Chem Biol 8:513-518. http://dx.doi.org/10.1021 /cb3006193.
49. Wagner R, Heuer D, Wolff T, Herwig A, Klenk HD. 2002. N-glycans attached to the stem domain of haemagglutinin efficiently regulate influenza A virus replication. J Gen Virol 83:601-609. http://dx.doi.org/10 .1099/0022-1317-83-3-601.
50. Wang G, Deval J, Hong J, Dyatkina N, Prhavc M, Taylor J, Fung A, Jin Z, Stevens SK, Serebryany V, Liu J, Zhang Q, Tam Y, Chanda SM, Smith DB, Symons JA, Blatt LM, Beigelman L. 2015. Discovery of 4=-chloromethyl-2=-deoxy-3=,5=-di-O-isobutyryl-2=-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem 58:1862-1878. http://dx.doi.org/10.1021/jm5017279.
51. Jordan R, Shao M, Mackman RL, Perron M, Cihlar T, Lewis SA, Eisenberg EJ, Carey A, Strickley RG, Chien JW, Anderson ML, McEligot HA, Behrens NE, Gershwin LJ. 2015. Antiviral efficacy of a respiratory syncytial virus (RSV) fusion inhibitor in a bovine model of RSV infection. Antimicrob Agents Chemother 59:4889-4900. http://dx.doi.org/10.1128 /AAC.00487-15.
52. Henrich TJ, Kuritzkes DR. 2013. HIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol 3:51-57. http://dx.doi.org/10 .1016/j.coviro.2012.12.002.
53. Hoffman LR, Kuntz ID, White JM. 1997. Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity. J Virol 71:8808 -8820.
54. Bodian DL, Yamasaki RB, Buswell RL, Stearns JF, White JM, Kuntz ID. 1993. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 32:2967-2978. http://dx.doi.org/10.1021/bi00063a007.
55. Plotch SJ, O'Hara B, Morin J, Palant O, LaRocque J, Bloom JD, Lang SA, Jr, DiGrandi MJ, Bradley M, Nilakantan R, Gluzman Y. 1999. Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J Virol 73:140-151.
56. Minagawa K, Kouzuki S, Kamigauchi T. 2002. Stachyflin and acetylstachyflin, novel anti-influenza A virus substances, produced by Stachybotrys sp. RF-7260. II. Synthesis and preliminary structure-activity relationships of stachyflin derivatives. J Antibiot 55:165-171.
57. Luo G, Colonno R, Krystal M. 1996. Characterization of a hemagglutinin-specific inhibitor of influenza A virus. Virology 226:66-76. http://dx .doi.org/10.1006/viro.1996.0628.
58. Staschke KA, Hatch SD, Tang JC, Hornback WJ, Munroe JE, Colacino JM, Muesing MA. 1998. Inhibition of influenza virus hemagglutininmediated membrane fusion by a compound related to podocarpic acid. Virology 248:264-274. http://dx.doi.org/10.1006/viro.1998.9273.
59. Russell RJ, Kerry PS, Stevens DJ, Steinhauer DA, Martin SR, Gamblin SJ, Skehel JJ. 2008. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A 105:17736-17741. http://dx.doi.org/10.1073/pnas.0807142105.
60. Weisshaar M, Cox R, Plemper RK. 2015. Blocking respiratory syncytial virus entry: a story with twists. DNA Cell Biol 34:505-510. http://dx.doi .org/10.1089/dna.2015.2896.
61. Yan D, Lee S, Thakkar VD, Luo M, Moore ML, Plemper RK. 2014. Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors. Proc Natl Acad Sci U S A 111:E3441-E3449. http://dx.doi.org/10.1073/pnas.1405198111.
62. Battles MB, Langedijk JP, Furmanova-Hollenstein P, Chaiwatpongsakorn S, Costello HM, Kwanten L, Vranckx L, Vink P, Jaensch S, Jonckers TH, Koul A, Arnoult E, Peeples ME, Roymans D, McLellan JS. 2016. Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat Chem Biol 12:87-93. http://dx.doi.org/10.1038/nchembio.1982.
63. Cox R, Plemper RK. 2016. Structure-guided design of small-molecule therapeutics against RSV disease. Expert Opin Drug Discov 2016:1-14.
64. Xu R, Wilson IA. 2011. Structural characterization of an early fusion intermediate of influenza virus hemagglutinin. J Virol 85:5172-5182. http: //dx.doi.org/10.1128/JVI.02430-10.
65. Bullough PA, Hughson FM, Skehel JJ, Wiley DC. 1994. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371:37-43. http://dx.doi.org/10.1038/371037a0.
66. Gruenke JA, Armstrong RT, Newcomb WW, Brown JC, White JM. 2002. New insights into the spring-loaded conformational change of influenza virus hemagglutinin. J Virol 76:4456-4466. http://dx.doi.org/10 .1128/JVI.76.9.4456-4466.2002.
67. Steinhauer DA, Sauter NK, Skehel JJ, Wiley DC. 1992. Receptor binding and cell entry by influenza viruses. Semin Virol 3:91-100.